Benchmark Reiterates Hold Rating on Neogenomics (NEO) on 2025 Revenue Guidance

Benchmark analyst Bruce Jackson reiterated a Hold rating on Neogenomics (NASDAQ: NEO).

The analyst commented: "NeoGenomics introduced 2025 revenue guidance of $735-745 million with Adjusted EBIDTA of $55-58 million ahead of its presentation today at an investor conference. The company also plans for 100-150 bps of gross margin improvement. We are raising our 2025 revenue estimate to $735 million from $719 million and our new Adjusted EBITDA estimate is $53 million, up from $52 million. While positive, we still view the shares as fairly valued given the below-comp-group margins and are maintaining our Hold rating."

For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.

Shares of Neogenomics closed at $14.71 yesterday.

You May Also Be Interested In

• Infinity Natural Resources, Inc. (INR) Tops Q2 EPS by 11c
• NioCorp feasibility study projects $4.1B NPV for Nebraska mine
• Orchestra BioMed (OBIO) Tops Q2 EPS by 1c